Actively Recruiting
Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
Led by Cairo University · Updated on 2026-02-05
28
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
CONDITIONS
Official Title
Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS)
- Presence of active myofascial trigger points in accessible muscles such as masseter, temporalis, or upper trapezius
- Pain lasting 3 months or longer
- Pain intensity of 4 or higher on the Visual Analog Scale (VAS)
- No trigger point injections in the affected area within the past 3 months
- Ability and willingness to provide informed consent
- Willingness to comply with study visits and procedures
You will not qualify if you...
- Allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents
- Use of anticoagulants or history of bleeding disorders
- Presence of systemic or local infection at or near the injection site
- History of fibromyalgia, central pain syndromes, or cancer-related pain
- Major psychiatric illnesses such as schizophrenia or severe depression
- Recent surgery or trauma to the head, neck, or upper back within the past 6 months
- Use of analgesics (NSAIDs, opioids) within 5 days before the intervention
- Severe systemic diseases including uncontrolled diabetes, liver or kidney failure, or severe cardiovascular conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty of oral and dental medicine, cairo university
Giza, Giza Governorate, Egypt, 12613
Actively Recruiting
Research Team
M
Maii E Abdelazeem, BSc
CONTACT
K
Khaled A Elhayes, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here